Table 3 International prescription habits for specific presentations/conditions
UK (n = 124) | Australia (n = 79) | New Zealand (n = 32) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Not treated | No FOs | Simple FOs | PFFOs | CFFOs | Not treated | No FOs | Simple FOs | PFFOs | CFFOs | Not treated | No FOs | Simple FOs | PFFOs | CFFOs | |
1. Back pain | 40 (32.3%) | 12 (9.7%) | 8 (6.5%) | 45 (36.3%) | 19 (15.3%) | 15 (19%) | 3 (3.8%) | 3 (3.8%) | 19 (24.1%) | 39 (49.4%) | 12 (37.5%) | 2 (6.3%) | 0 (0%) | 14 (43.8%) | 4 (12.5%) |
2. Hip pain | 34 (27.4%) | 11 (8.9%) | 7 (5.6%) | 51 (41.1%) | 21 (16.9%) | 11 (13.9%) | 9 (11.4%) | 1 (1.3%) | 18 (22.8%) | 40 (50.6%) | 7 (21.9%) | 0 (0%) | 0 (0%) | 21 (65.6%) | 4 (12.5%) |
3. Knee pain | 19 (15.3%) | 4 (3.2%) | 9 (7.3%) | 75 (60.5%) | 17 (13.7%) | 3 (3.8%) | 1 (1.3%) | 1 (1.3%) | 25 (31.6%) | 49 (62%) | 3 (9.4%) | 0 (0%) | 1 (3.1%) | 24 (75%) | 4 (12.5%) |
4. Patello-femoral pain | 26 (21%) | 5 (4%) | 6 (4.8%) | 71 (57.3%) | 16 (12.9%) | 3 (3.8%) | 3 (3.8%) | 0 (0%) | 25 (31.6%) | 48 (60.8%) | 2 (6.3%) | 0 (0%) | 1 (3.1%) | 26 (81.3%) | 3 (9.4%) |
5. Shin splints | 17 (13.7%) | 6 (4.8%) | 8 (6.5%) | 74 (59.7%) | 19 (15.3%) | 2 (2.5%) | 1 (1.3%) | 0 (0%) | 28 (35.4%) | 48 (60.8%) | 1 (3.1%) | 1 (3.1%) | 0 (0%) | 23 (71.9%) | 7 (21.9%) |
6. Ankle pain | 9 (7.3%) | 6 (4.8%) | 11 (8.9%) | 70 (56.5%) | 28 (22.6%) | 1 (1.3%) | 4 (5.1%) | 1 (1.3%) | 22 (27.8%) | 51 (64.6%) | 0 (0%) | 0 (0%) | 0 (0%) | 24 (75%) | 8 (25%) |
7. Achilles tendonitis | 10 (8.1%) | 7 (5.6%) | 17 (13.7%) | 76 (61.3%) | 14 (11.3%) | 1 (1.3%) | 5 (6.3%) | 8 (10.1%) | 28 (35.4%) | 37 (46.8%) | 0 (0%) | 4 (12.5%) | 0 (0%) | 24 (75%) | 4 (12.5%) |
8. Rearfoot pain | 8 (6.5%) | 4 (3.2%) | 17 (13.7%) | 74 (59.7%) | 21 (16.9%) | 2 (2.5%) | 1 (1.3%) | 0 (0%) | 32 (40.5%) | 44 (55.7%) | 0 (0%) | 1 (3.1%) | 0 (0%) | 23 (71.9%) | 8 (25%) |
9. Plantar heel pain / plantar fasciitis | 5 (4%) | 5 (4%) | 23 (18.5%) | 76 (61.3%) | 15 (12.1%) | 2 (2.5%) | 1 (1.3%) | 0 (0%) | 35 (44.3%) | 41 (51.9%) | 0 (0%) | 0 (0%) | 0 (0%) | 25 (78.1%) | 7 (21.9%) |
10. Peroneal tendonitis | 13 (10.5%) | 5 (4%) | 13 (10.5%) | 64 (51.6%) | 29 (23.4%) | 3 (3.8%) | 5 (6.3%) | 5 (6.3%) | 22 (27.8%) | 44 (55.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 25 (78.1%) | 7 (21.9%) |
11. Tibialis posterior tendon dysfunction | 10 (8.1%) | 1 (0.8%) | 11 (8.9%) | 58 (46.8%) | 44 (35.5%) | 2 (2.5%) | 1 (1.3%) | 0 (0%) | 16 (20.3%) | 60 (75.9%) | 0 (0%) | 0 (0%) | 0 (0%) | 13 (40.6%) | 19 (59.4%) |
12. Midfoot pain/OA | 9 (7.3%) | 1 (0.8%) | 19 (15.3%) | 54 (43.5%) | 41 (33.1%) | 2 (2.5%) | 1 (1.3%) | 2 (2.5%) | 33 (41.8%) | 41 (51.9%) | 0 (0%) | 0 (0%) | 1 (3.1%) | 18 (56.3%) | 13 (40.6%) |
13. Forefoot pain/meta-tarsalgia | 7 (5.6%) | 4 (3.2%) | 44 (35.5%) | 50 (40.3%) | 19 (15.3%) | 3 (3.8%) | 1 (1.3%) | 11 (13.9%) | 36 (45.6%) | 28 (35.4%) | 0 (0%) | 0 (0%) | 4 (12.5%) | 22 (68.8%) | 6 (18.8%) |
14. Morton’s neuroma | 8 (6.5%) | 5 (4%) | 45 (36.3%) | 47 (37.9%) | 19 (15.3%) | 3 (3.8%) | 5 (6.3%) | 14 (17.7%) | 30 (38%) | 27 (34.2%) | 0 (0%) | 1 (3.1%) | 8 (25%) | 19 (59.4%) | 4 (12.5%) |
15. 1st MTPJ OA | 5 (4%) | 4 (3.2%) | 28 (22.6%) | 63 (50.8%) | 24 (19.4%) | 2 (2.5%) | 2 (2.5%) | 4 (5.1%) | 23 (29.1%) | 48 (60.8%) | 0 (0%) | 0 (0%) | 1 (3.1%) | 19 (59.4%) | 12 (37.5%) |
16. Diabetes without peripheral neuropathy | 9 (7.3%) | 19 (15.3%) | 29 (23.4%) | 48 (38.7%) | 19 (15.3%) | 3 (3.8%) | 25 (31.6%) | 9 (11.4%) | 23 (29.1%) | 19 (24.1%) | 4 (12.5%) | 2 (6.3%) | 2 (6.3%) | 22 (68.8%) | 2 (6.3%) |
17. Diabetes with peripheral neuropathy | 15 (12.1%) | 11 (8.9%) | 29 (23.4%) | 28 (22.6%) | 41 (33.1%) | 5 (6.3%) | 14 (17.7%) | 13 (16.5%) | 17 (21.5%) | 30 (38%) | 5 (15.6%) | 1 (3.1%) | 5 (15.6%) | 15 (46.9%) | 6 (18.8%) |
18. Non-inflammatory musculoskeletal disease | 5 (4%) | 4 (3.2%) | 25 (20.2%) | 72 (58.1%) | 18 (14.5%) | 2 (2.5%) | 3 (3.8%) | 5 (6.3%) | 32 (40.5%) | 37 (46.8%) | 0 (0%) | 1 (3.1%) | 2 (6.3%) | 23 (71.9%) | 6 (18.8%) |
19. Sero-negative inflammatory arthritis | 22 (17.7%) | 10 (8.1%) | 11 (8.9%) | 42 (33.9%) | 39 (31.5%) | 11 (13.9%) | 7 (8.9%) | 4 (5.1%) | 20 (25.3%) | 37 (46.8%) | 8 (25%) | 0 (0%) | 5 (15.6%) | 12 (37.5%) | 7 (21.9%) |
20. Gout | 20 (16.1%) | 33 (26.6%) | 23 (18.5%) | 37 (29.8%) | 11 (8.9%) | 10 (12.7%) | 28 (35.4%) | 7 (8.9%) | 18 (22.8%) | 16 (20.3%) | 8 (25%) | 4 (12.5%) | 0 (0%) | 17 (53.1%) | 3 (9.4%) |
21. Connective tissue disease | 28 (22.6%) | 24 (19.4%) | 20 (16.1%) | 28 (22.6%) | 24 (19.4%) | 16 (20.3%) | 19 (24.1%) | 3 (3.8%) | 22 (27.8%) | 19 (24.1%) | 6 (18.8%) | 2 (6.3%) | 4 (12.5%) | 16 (50%) | 4 (12.5%) |
22. Neurological diseases | 27 (21.8%) | 21 (16.9%) | 18 (14.5%) | 27 (21.8%) | 31 (25%) | 12 (15.2%) | 15 (19%) | 2 (2.5%) | 15 (19%) | 35 (44.3%) | 7 (21.9%) | 2 (6.3%) | 2 (6.3%) | 11 (34.4%) | 10 (31.3%) |
23. Neuro-muscular conditions | 27 (21.8%) | 22 (17.7%) | 19 (15.3%) | 25 (20.2%) | 31 (25%) | 10 (12.7%) | 20 (25.3%) | 4 (5.1%) | 17 (21.5%) | 28 (35.4%) | 8 (25%) | 3 (9.4%) | 3 (9.4%) | 10 (31.3%) | 8 (25%) |
24. Falls prevention in older adults | 26 (21%) | 22 (17.7%) | 19 (15.3%) | 46 (37.1%) | 11 (8.9%) | 7 (8.9%) | 21 (26.6%) | 4 (5.1%) | 28 (35.4%) | 19 (24.1%) | 8 (25%) | 5 (15.6%) | 0 (0%) | 15 (46.9%) | 4 (12.5%) |